Diabetic Retinopathy Clinical Trial
Official title:
A Multicenter Study to Evaluate the Performance of Automated Retinal Disease Assessment Software for the Detection of More Than Mild Diabetic Retinopathy
NCT number | NCT04905459 |
Other study ID # | 101703 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 30, 2021 |
Est. completion date | May 23, 2022 |
Verified date | June 2022 |
Source | Verily Life Sciences LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a multicenter, observational study with primary endpoints to determine the sensitivity and specificity of two investigational software devices that detect the presence of more than mild diabetic retinopathy (mtmDR) in healthcare settings.
Status | Completed |
Enrollment | 1012 |
Est. completion date | May 23, 2022 |
Est. primary completion date | May 23, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: 1. Documented diagnosis of Type I or Type II diabetes mellitus: meet the criteria established by either the World Health Organization (WHO) or the American Diabetes Association (ADA) 2. Age 22 or older 3. Understand the study and volunteer to sign the informed consent Exclusion Criteria: 1. Self-reported visual symptoms and persistent blurred vision (greater than 24 hours); including vision loss that cannot be corrected (e.g. with eye glasses). 2. Diagnosed with macular edema, any known retinopathy, radiation retinopathy, or retinal vein occlusion. 3. History of laser treatment of the retina or injections into either eye, or any history of retinal surgery. 4. Scheduled to undergo the following surgeries before completion of the study imaging: cataract surgery (including any related follow-up procedures) or vitrectomy. 5. Currently participating in an interventional study. 6. Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation, etc.). 7. Participant is contraindicated for imaging by fundus imaging system used in the study; e.g. 1. Participant is hypersensitive to light (side effect of medication or due to unknown etiology) 2. Participant has undergone photodynamic therapy (PDT) 3. Previous issues with dilation (angle closure, inability to dilate, allergy to dilation drops). 8. Known pregnancy or possibility of pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | MedStar Health Research Institute Baltimore | Baltimore | Maryland |
United States | Diabetes & Endocrinology Associates of Stark County, Inc | Canton | Ohio |
United States | Christie Clinic | Champaign | Illinois |
United States | Northwestern University | Chicago | Illinois |
United States | The Heart and Medical Center, P.C | Durant | Oklahoma |
United States | Midwestern University | Glendale | Arizona |
United States | Clinical Trials Network | Houston | Texas |
United States | NEA Baptist Clinic | Jonesboro | Arkansas |
United States | Western Michigan University | Kalamazoo | Michigan |
United States | BMG The Endocrine Clinic | Memphis | Tennessee |
United States | Catalina Research Institute | Montclair | California |
United States | Riverside Diabetes Clinic | Riverdale | Maryland |
United States | PMG Research of Winston Salem | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Verily Life Sciences LLC | Google LLC., Nikon Corporation, Optos, PLC, The Emmes Company, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity of ARDA mtmDR for detection of mtmDR in 45 degree images | 1 day | ||
Primary | Specificity of ARDA mtmDR for detection of mtmDR in 45 degree images | 1 day | ||
Primary | Sensitivity of ARDA mtmDR for detection of mtmDR in UWF images | 1 day | ||
Primary | Specificity of ARDA mtmDR for detection of mtmDR in UWF images | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03660371 -
ILM Peeling in PDR Patients Undergoing PPV for VH
|
N/A | |
Completed |
NCT03660384 -
Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy
|
N/A | |
Completed |
NCT03660345 -
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
|
Phase 3 | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT05022615 -
Comparing 3 Imaging Systems
|
||
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT03702374 -
Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy
|
Phase 3 | |
Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
Completed |
NCT04009980 -
Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus.
|
N/A | |
Completed |
NCT02924311 -
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
|
||
Not yet recruiting |
NCT06257082 -
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
|
N/A | |
Not yet recruiting |
NCT05452993 -
Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography
|
N/A | |
Withdrawn |
NCT02812030 -
Aflibercept for Retinopathy in the Real World
|
N/A | |
Completed |
NCT02391558 -
Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography
|
N/A | |
Active, not recruiting |
NCT02353923 -
OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy
|
N/A | |
Active, not recruiting |
NCT02330042 -
OCT Biomarkers for Diabetic Retinopathy
|
||
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT01950663 -
RETeval Study for Diabetic Retinopathy
|
N/A |